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Guillain–Barré syndromea b s t r a c t
The global SARS-CoV-2 pandemic posed an unprecedented challenge to almost all fields of medicine and
Neurology is not an exception. Collecting information about its complications and related conditions will
help clinicians to become more confident in managing this disease. Guillain-Barre Syndrome (GBS) is
mostly described as a post-infectious phenomenon and its occurrence during acute phase of illness is
of interest. GBS has recently been reported during the active phase of COVID-19 for the first time.
Severity and fast progression of GBS associated with COVID-19 have also been shown in recent studies.
Here we report three cases of GBS during the active phase of COVID-19 with severe symptoms and fast
progression to quadriplegia and facial diplegia over 2 days, which led to death in one case due to severe
autonomic dysfunction. We suggest SARS-CoV-2 might be associated with rather a severe, rapidly pro-
gressive and life-threatening phenotype of GBS.
 2020 Elsevier Ltd. All rights reserved.1. Introduction
Coronavirus disease 2019 (COVID-19) is defined as an illness
caused by a novel coronavirus, which is now called severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called
2019-nCoV). SARS-CoV-2 was first identified at an outbreak of res-
piratory illness cases in Wuhan City, Hubei Province, China. It was
initially reported to the World Health Organization (WHO) on
December 31, 2019 [1]. On January 30, 2020, the WHO declared
the COVID-19 outbreak as a global health emergency [2,3].
Since August 16, 2020, the COVID-19 pandemic has resulted in
more than 21 million of confirmed cases worldwide. Additionally,Iran stands on the 11th rank in terms of infected cases by SARS-
CoV-2, with more than 341,000 infected cases [4].
Guillain-Barré Syndrome (GBS) is considered mostly a post-
infectious, immune-mediated disease. Symptoms of a preceding
upper respiratory tract infection or gastrointestinal infection are
often reported prior to the onset of GBS symptomatology. How-
ever, it might also occur during the infectious phase in some cases.
The first case of GBS during the COVID-19 pandemic has recently
been published, and since then investigations on its relationship
to COVID-19 have started [5]. Molecular mimicry between infec-
tious agents and gangliosides plays a crucial role in inducing these
antibodies [6,7].
2. Case1
An 88-year old woman was admitted to the emergency depart-
ment in April 2020 with quadriparesis. Her symptoms started with
acute paraparesis, which progressed to quadriparesis within two
days. She did not report cough, dyspnea, fever, diarrhea, paresthe-
sia or urinary symptoms. She was complaining of severe fatigue,
low back pain and pain in her thighs. Her past medical history
was significant for hypertension. On physical examination, she
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closure weakness and neck flexion weakness. An evaluation of
muscle power revealed Medical Research Council (MRC) grade
2/5 in the muscles of upper limbs and MRC 3/5 in lower limbs.
Deep tendon reflexes were absent in lower limbs and depressed
in upper limbs. Sensory examination revealed impaired proprio-
ception. Spinal tap was performed on day two of admission, and
cerebrospinal fluid (CSF) analysis showed an elevated protein level
(88 mg/dl) with no cells in accordance with albuminocytologic dis-
sociation. Antigangliosides antibodies were not checked. She
underwent electromyography, and nerve conduction studies
(EMG-NCS) revealed features consistent with an acute motor and
sensory axonal neuropathy (AMSAN) subtype of GBS (Table 1).
She was admitted in the intensive care unit (ICU) due to autonomic
instability, and plasma exchange was started. On the third day of
admission, she was intubated owing to respiratory distress, and
her chest computed tomography (CT) scan revealed pneumonia
with a ground glass pattern suggestive of corona virus infection.
COVID-19 polymerase chain reaction (PCR) returned positive;
therefore, she was isolated. She was commenced on Dexametha-
sone, along with Hydroxychloroquine and Lopinavir/Ritonavir for
the treatment of COVID-19. Minimal improvement in muscle
power was achieved after 6 sessions of plasma exchange 2 weeks
after commencing the treatment. She was discharged upon
improvement of respiratory symptoms.3. Case 2
Our second patient was a 47-year-old man who was admitted
to the emergency department by his family with generalized
weakness and dysarthria in April 2020. His family provided a his-
tory of 10 days of dyspnea and cough prior to the emergence of
his dysarthria that led to hospital presentation. He appeared ill,
but he was afebrile. On neurologic examinations, a mild muscle
weakness and generalized hyporeflexia were found together with
dysarthria. MRI brain and whole spine results were normal. The
CT scan of his chest was consistent with COVID-19 infection. There
was elevated CRP and leukopenia on his blood examination. The
patient was admitted in an isolated ward, and Dexamethasone,
Hydroxychloroquine and Lopinavir/Ritonavir were started to treat
COVID-19. On the second day of admission, a neurology consult
was requested as the patient developed urinary retention. The
patient complained of severe low back pain. On examination, he
had quadriparesis and weakness in neck flexors. He was areflexic.
Based on his EMG-NCS (Table 2), an AMSAN type of GBS was diag-Table 1
Nerve conduction study parameters in case 1.



























Median (s) Wrist Index finger 8
Ulnar (s) wrist Little finger 6
Sural (s) calf Post. calf NR
*Motor = mV, Sensory = mV; ms = milli second, Rt = right; Lt = left; AF = anterior fossa; B
APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis
120nosed. Hence, treatment with plasma exchange was started. The
CSF analysis revealed elevated protein with the level of 154 mg/
dl and no cells. Antigangliosides antibodies were not checked.
One day during his treatment, he developed bilateral facial palsy.
The patient was intubated due to respiratory distress on the same
day and was transferred to ICU. On the 4th day of admission and
after 2 sessions of plasma exchange, the patient died from severe
autonomic dysfunction.4. Case 3
A 58-year-old man was admitted to the emergency department
in April 2020, with a two-day history of progressive dyspnea, dry
cough and dizziness. Vital signs on presentation were remarkable
for the respiratory rate of 26 breaths per minute with oxygen sat-
uration of 88% on room air. The patient was admitted to the hospi-
tal with the impression of COVID-19 infection. Chest CT-scan
results were consistent with the diagnosis of COVID-19, which
was confirmed by a positive nasopharyngeal PCR test. He was
admitted to ICU for respiratory support and was treated with avail-
able suggested drugs for COVID-19 such as Remdesivir, Hydroxy-
chloroquine, Favipiravir and Lopinavir/Ritonavir. On the 7th day
of admission, he developed muscle weakness, gait disturbance
and areflexia. EMG/NCV findings were suggestive of an AMSAN
sub-type of GBS (Table 3). CSF was acellular with elevated protein
(65 mg/dl). Antigangliosides antibodies were not checked. Intra-
venous immunoglobulin (0.4 g/kg, for 2 days) was commenced
for the patient.
Two days later, he was switched to plasma exchange due to a
rise in serum creatinine. The patient developed severe respiratory
distress and became intubated 14 days after his admission. We
assumed that GBS caused ventilation problems as well as respira-
tory problems. The patient died on the 20th day of admission due
to multi-organ failure.5. Discussion
Since the outbreak of COVID-19 in China, there have been sev-
eral case reports of its neurological complications such as acute
stroke, encephalopathy and skeletal muscle injury [8]. GBS is a
well-known post/para-infectious entity. Recently, Ellul et al. have
proposed a probable association of GBS with SARS-CoV-2 infection
where onset of weakness was 6 weeks after acute infection [9].
COVID-19-ralated GBS was first reported in China and was
assumed to have a para-infectious profile rather than a post-e Latency (ms) Conduction
velocity (m/s)
F wave (ms)
Lt Rt Lt Rt Lt Rt Lt
3.6
3.2
4.1 4 40 40 32 32
4.1 3.1 3 48 48 32 32
NR NR NR NR NR NR NR
NR NR NR NR NR NR NR
7 3.4 3.5 38 38
6 3 3.1 40 40
NR NR NR NR NR
E = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa;
brevis; EDB = extensor digitorum brevis; NR = not response.
Table 2
Nerve conduction study parameters in case 2.
































NR NR NR NR NR NR NR NR
Median (s) Wrist Index finger NR NR NR NR NR NR
Ulnar (s) wrist Little finger NR NR NR NR NR NR
Sural (s) calf Post. calf NR NR NR NR NR NR
*Motor = mV, Sensory = mV; ms = milli second, Rt = right; Lt = left; AF = anterior fossa; BE = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa;
APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis brevis; EDB = extensor digitorum brevis; NR = not response.
Table 3
Nerve conduction study parameters in case 3.
































NR NR NR NR NR NR NR NR
Median (s) Wrist Index finger NR NR NR NR NR NR
Ulnar (s) wrist Little finger NR NR NR NR NR NR
Sural (s) calf Post. calf NR NR NR NR NR NR
* Motor = mV, Sensory = mV; ms = milli second, Rt = right; Lt = left; AF = anterior fossa; BE = below elbow; AE = above elbow; BF = below fibula; LPF = lateral posterior fossa;
APB = abductor pollicis brevis; ADM = abductor digiti minimi; AHB = abductor hallucis brevis; EDB = extensor digitorum brevis; NR = not response.
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CoV-19 was reported from Iran. The case was a 65-year-old man
with severe progressive peripheral neuropathy leading to
quadriplegia, two weeks after COVID-19 diagnosis based on a pos-
itive PCR [11]. Alberti et al. reported the second case of parainfec-
tious SARS-CoV-2-related GBS in a patient presenting
simultaneous neurological and respiratory symptoms where the
patient died from respiratory failure despite appropriate treatment
[12]. De Sanctis et al., by investigating the characteristics of 18 GBS
patients associated with SARS-CoV-2 reported around the world,
published a systematic review published on the 5th August 2020.
Ten patients were male and 8 were female with a mean age of
62 years. Cough and fever were the most frequent observed symp-
toms of SARS-CoV-2 infection among the patients (72.2%). Concur-
rent symptoms of GBS and SARS-CoV-2 infection were observed in
five patients (27.8%). The frequency of different electrophysiologi-
cal subtypes was as follows: Acute inflammatory demyelinating
polyneuropathy (AIDP) (10 patients), AMSAN (4 patients), acute
motor axonal neuropathy (AMAN) (1 patient) and not reported (3
patients). Death and poor prognosis were reported in two (11.1%)
and four cases (22.2%), respectively, due to GBS and concurrent
complications caused by COVID-19. However, the prognosis was
not reported in three cases. All reported patients in this study
received intravenous immunoglobulin (IVIg) except for two
(88.9%); while one underwent plasma exchange after IVIg therapy.121[13]. Here, we reported three cases of GBS during the active phase
of COVID-19 pandemic. Since all of our patients had the symptoms
of GBS during the active phase of Corona virus infection, we reiter-
ate the proposed theory of GBS being a para-infectious condition in
association with COVID-19 infection. (Table 4). As exhibited in
these patients, the fast progression and severity of GBS in such
cases are significant, as demonstrated in a recent study where 4
out of 5 patients diagnosed with GBS after SARS-CoV-19 infection
developed tetraplegia over a period of 36 h to 4 days [5]. While
symptoms of GBS were developed after COVID-19 in these
patients, one of our cases presented with GBS symptomatology
before the onset of COVID-19 symptoms. A similar encounter has
been reported in association with Zika virus during its outbreak
in 2016 [14,15]. Facial palsy and higher CSF protein levels with sev-
ere GBS have been reported in the outbreak of Zika virus [16].
Similarities might be seen in some close viral pathogens; there-
fore, it is necessary for clinicians to learn from past outbreaks, such
as Middle East respiratory syndrome (MERS) and Zika epidemics,
where neuromuscular complications were not rare [17]. COVID-
19 should be considered in differential diagnoses of rare neuro-
muscular presentations during the pandemic period. We suggest
a full investigation panel to rule out COVID-19 infection in patients
presenting with GBS, including rare subtypes. Furthermore,
patients presenting with COVID-19 should undergo detailed neu-
rological examinations to specifically seek features of GBS. A severe
Table 4
Characteristics of Three Patients with Guillain–Barré Syndrome after the Onset of Covid-19.
Patient
No.
Characteristics Onset of Neurologic
symptoms





two days prior to admission
with severe fatigue and low
back pain
Paraparesis developed to quadriparesis,
absent DTR in lower limbs and decreased













About a week prior to
admission, coincide with
respiratory symptoms
Dysarthria and decreased DTR in lower












7 days followed by
admission










Death on the 20th day
of admission
CSF, cerebrospinal fluid; EDX, electrodiagnosis; DTR, deep tendon reflex; RBC, red blood cell; WBC, white blood cell; AMSAN, acute motor-sensory axonal neuropathy; IVIg,
intravenous immune globulin.
M. Abolmaali, M. Heidari, M. Zeinali et al. Journal of Clinical Neuroscience 83 (2021) 119–122and rapid progressive phenotype of GBS appears to be another neu-
rologic complication of COVID-19 with the possibility of occur-
rence during the active phase of the disease.
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